Los Angeles-based ViaDerma is on a mission to continually develop, license, and scale out their innovative transdermal drug delivery system offerings to leaders in healthcare globally. Founded back in 2014 by Dr. Christopher Otiko, ViaDerma, a publicly traded specialty pharmaceutical company has been developing & licensing the world’s strongest broad-spectrum topical antibiotics for treating wounds and a variety of infectious diseases.
Their innovative, patent-pending dual-carrier transdermal drug delivery technology system can be used to transform oral medications into topical ointments and deliver very rapid results to the desired site that requires treatment.
ViaDerma specializes in the use of strong Advanced Biological Coverage (ABC) topical antibiotics that are highly concentrated, penetrate faster, and are much more effective than conventional antibiotics. Their advanced transdermal delivery system quickly kills all harmful gram-positive & gram-negative bacteria that have been available for testing over the past 10 years, while delivering results within 24 hours, when compared to 5-7 days (if ever) against many other brand name products currently out in the market.
Their transdermal drug delivery solutions effectively facilitate the transfer of chemicals through the stratum corneum with a diffusion constant that is 10,000x higher, while the dual carrier liquid can possess long-lasting life enhancing technology with up to a 2-year shelf life. All while producing far more effective results than many leading brand name competitors.
Furthermore, ViaDerma’s transdermal drug technology system can be used in many fields of business, including cosmetics, first aid products, wound care, sports supplements, medical marijuana, along with treating common bacterial skin diseases like acne, eczema, and psoriasis too. Their solutions, like lead product Vitastem Ultra have helped heal diabetic ulcers and have saved countless amputations to date. In addition to wound care, Vitastem Ultra can be used to treat 1st to 3rd degree burns, boils, shingles, and antibiotic resistant bacteria like staph and MRSA (flesh-eating bacteria).
Presently, their Vitastem Ultra first aid & topical antibiotic spray is used within the OTC drug market, and available to use without a prescription as provided by the patient’s physician. ViaDerma believes that their topical delivery system can be used for the prescription medication market as well not only for topical prescription medications but also to turn certain oral medications into topically based medications, which are far safer for one’s kidneys and other organs.
Vitastem seems to work wonders at healing serious wounds according to healthcare professionals.
“Vitastem has been a miracle worker on my patients’ wounds. In the 9 months I have been using it, I have not seen one infection of the wounds. Patients love it, and so do I. Easy application and extremely effective.” said Judi Miller, FNP, at The Wound Pros.
In addition to fighting infectious skin diseases and healing minor to serious wounds with Vitastem Ultra, there is still more coming out of ViaDerma as the company recently announced they will be getting into the hair restoration market this year, as they plan to launch their new hair regrowth product, Nupelo, sometime around the end of Q2 2023.
ViaDerma founder & CEO, Dr. Otiko had this to say about it, “Everything has really come together very quickly and smoothly. Due to the extreme effectiveness of our proprietary transdermal delivery system, we are able to develop new products like Nupelo in a very short period of time. Many other hair products only work to reduce hair loss but are ineffective at actually regrowing hair. Nupelo works to solve both.” We’ll continue to follow the progress of ViaDerma’s journey to becoming a key player in the healthcare industry and look forward to seeing great progress made for all those suffering from serious wounds & infectious skin diseases with the accelerated adoption and use of products like Vitastem Ultra, along with men & women being able to regrow their hair with Nupelo, once it launches to the public.
